• Explore /
  • Poster
  • / Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Abstract Video & Slides Poster

Authors

null

Timothy Lewis Cannon

Inova Schar Cancer Institute, Fairfax, VA;

Timothy Lewis Cannon , Michael Rothe , Elizabeth Garrett-Mayer , Vi Kien Chiu , Jimmy J. Hwang , Namrata Vijayvergia , Olatunji B. Alese , Elie G. Dib , Herbert Leon Duvivier , Kelsey Klute , Vaibhav Sahai , Eugene R Ahn , Deepti Behl , Sarah Sinclair , Ramya Thota , Walter John Urba , Eddy Shih-Hsin Yang , Gina N. Grantham , Susan Halabi , Richard L. Schilsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02693535

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 546)

DOI

10.1200/JCO.2023.41.4_suppl.546

Abstract #

546

Poster Bd #

C16

Abstract Disclosures

Similar Posters

First Author: Deepti Behl

First Author: Tareq Al Baghdadi

First Author: Gordan Srkalovic

First Author: Do-Youn Oh